Dare Bioscience, Inc. (DARE) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$0.66

From 52W high−78.93%

Volume169832.00

Market cap$13.55M

P/E (TTM)—

P/S (TTM)9.9x

Div yield—

Key dataNov 4, 2026

Open

$0.66

From 52W high

−78.93%

Volume

169832.00

Market cap

$13.55M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.9x

P/E (TTM)

—

RSI (14)

38.6

MomentumView details →

1D Return

+6.00%

YTD Return

−65.60%

SummaryUpdated Jun 1, 2026

Daré Bioscience, Inc. (NASDAQ:DARE) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in San Diego, California. The company focuses exclusively on developing and commercializing innovative healthcare products for women's health, addressing unmet medical needs across contraception, fertility, sexual health, and vaginal health. Since its IPO in April 2014, Daré has built a diverse pipeline of 12 development-stage candidates targeting nine different women's health indications, with its first FDA-approved product <b>XACIATO</b> launched commercially in 2024 through a partnership with Organon.

Ask drillr about Dare Bioscience, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.9x

EV/Sales

5.6x

P/S (TTM)

9.9x

P/B (TTM)

−24.2x

ProfitabilityView details →

Gross Margin

−89.45%

Net Margin

−804.37%

EBITDA Margin

−630.71%

ROE (TTM)

1961.64%

ROA (TTM)

−49.12%

Asset Turnover

0.05x

GrowthView details →

Revenue YoY

+7816.73%

EPS YoY

+63.28%

FCF YoY

+0.96%

Revenue CAGR 3Y

−53.12%

EPS CAGR 3Y

—

EBITDA YoY

+50.94%

MomentumView details →

1D Return

+6.00%

YTD Return

−65.60%

1Y Return

−63.92%

RSI (14)

38.6

vs 50D SMA

−10.31%

vs 200D SMA

−57.47%

Capital & dividendView details →

Debt/Equity

−12.08x

Current Ratio

0.99x

Quick Ratio

0.99x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.20

EPS Surprise

32.59%

Beats (12Q)

11/12

Next Q EPS Est

−$0.20

Avg Surprise (4Q)

44.70%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

1.37M

Net Income (TTM)

−10.99M

Op. CF (TTM)

−11.29M

Next earningsNov 12, 2026 →

Latest newsMore news →

Dare Bioscience, Inc. reported that it has surpassed $43 million in non-dilutive grant funding, including a latest $1.5 million installment, as DARE-LARC1 advances in preclinical development.5d ago

Daré Bioscience announced premier sponsorship of Dare Bioscience, Inc. and the Dare Bioscience, Inc.’s continuing medical education program on managing menopause after breast cancer.16d ago

Similar companies

BioCardia, Inc.BCDA Cuprina Holdings (Cayman) Limited Class A Ordinary SharesCUPR Adial Pharmaceuticals, Inc.ADIL TScan Therapeutics, Inc.TCRX Fractyl Health, Inc. Common StockGUTS NewcelX Ltd.NCEL Find similar companies →

Latest newsMore news →

Dare Bioscience, Inc. reported that it has surpassed $43 million in non-dilutive grant funding, including a latest $1.5 million installment, as DARE-LARC1 advances in preclinical development.5d ago Daré Bioscience announced premier sponsorship of Dare Bioscience, Inc. and the Dare Bioscience, Inc.’s continuing medical education program on managing menopause after breast cancer.16d ago